Exane BNP Paribas initiated coverage of Gerresheimer with an Outperform rating. The analyst says drug containment and delivery players operate within an attractive market.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GRRMF:
- Gerresheimer resumed with a Buy at Stifel
- Gerresheimer price target raised to EUR 125.70 from EUR 123.20 at JPMorgan
- Gerresheimer AG (0NTI) Q1 Earnings Cheat Sheet
- Gerresheimer price target lowered to EUR 125 from EUR 127 at Berenberg
- Gerresheimer price target raised to EUR 130 from EUR 126 at Deutsche Bank